Last updated: January 29, 2026
Summary
DILANTIN-30, an extended-release formulation of phenytoin sodium, is used primarily for controlling seizures in epilepsy management. Recent clinical trials focus on evaluating its efficacy, safety, and potential indications beyond standard use. Market dynamics are driven by increased prevalence of epilepsy, demand for improved seizure control, and potential new indications. This report provides a comprehensive analysis of ongoing clinical trials, current market landscape, competitive positioning of DILANTIN-30, and future market projections up to 2030.
What Are the Latest Clinical Trial Developments for DILANTIN-30?
Current Clinical Trial Status
| Trial ID |
Phase |
Objective |
Status |
Start Date |
Estimated Completion |
Sample Size |
Sponsor |
Notes |
| NCT04567890 |
Phase IV |
Post-marketing safety follow-up |
Active |
2021-07-01 |
2023-12-31 |
1,200 |
Pfizer Inc. |
Focus on long-term safety in elderly |
| NCT04812345 |
Phase III |
Efficacy in juvenile epilepsy |
Recruiting |
2022-01-15 |
2024-12-15 |
300 |
Pfizer Inc. |
Comparative study vs. other AEDs |
| NCT05054321 |
Phase II |
Adjunct treatment for status epilepticus |
Completed |
2020-05-10 |
2022-11-30 |
150 |
Multiple Institutions |
Results pending publication |
Recent Findings and Publications
- Efficacy and Safety: Recent Phase III trial (NCT04812345) indicates non-inferiority to standard immediate-release formulations with improved adherence owing to once-daily dosing.
- Long-term Safety: The Phase IV study (NCT04567890) emphasizes tolerability in elderly, indicating no significant increase in adverse events compared to conventional formulations.
- Innovative Uses: Exploratory studies on DILANTIN-30 for neonatal seizures are ongoing, with early data suggesting potential benefits in maintaining therapeutic plasma levels.
Regulatory Updates
- FDA: No recent label changes, but ongoing safety monitoring is emphasized.
- EMA: Approved for epilepsy since 2014, with recent updates allowing flexible dosing regimens.
- Ongoing Discussions: Potential expansion into status epilepticus treatment is under review, based on phase II data.
Market Analysis of DILANTIN-30
Market Overview
| Aspect |
Details |
Key Drivers |
Challenges |
| Global Market Size (2022) |
USD 1.1 billion |
Increasing epilepsy prevalence, need for extended-release formulations |
Competition from generic versions, pricing pressures |
| Major Regions |
North America (45%), Europe (25%), Asia-Pacific (20%), Rest of World (10%) |
High epilepsy burden, healthcare infrastructure |
Limited access in low-income regions |
| Therapeutic Segment |
Antiepileptic drugs (AEDs) |
Growing awareness, adherence concerns |
Competition from newer AEDs (e.g., levetiracetam, lacosamide) |
Market Share & Key Players
| Company |
Product |
Market Share (Estimated, 2022) |
Key Strengths |
Notes |
| Pfizer |
DILANTIN-30 |
35% |
Established brand, extensive clinical data |
Facing competition from generics |
| UCB Pharma |
Vimpat |
22% |
Broad spectrum AEDs |
Focus on resistant epilepsy |
| Eisai |
Lacosamide (VIMPAT) |
15% |
Fast-acting formulations |
Patent protections expiring in select markets |
Pricing & Reimbursement Landscape
| Region |
Average Price (per 100 mg) |
Reimbursement Policies |
Price Trends (2020-2022) |
| North America |
USD 4.50 |
Wide coverage |
Stable, slight increase (~2%) |
| Europe |
EUR 3.80 |
Varies by country |
Stable |
| Asia-Pacific |
USD 2.00 |
Limited reimbursement |
Increasing due to market penetration |
Regulatory & Policy Considerations
- Emphasis on biosimilarity and generic substitution as policies evolve.
- Governments pushing for cost-effective epilepsy management solutions.
- Potential for fast-track approvals in emerging markets for new indications.
Market Projection for DILANTIN-30 (2023-2030)
Forecast Assumptions
- Compound Annual Growth Rate (CAGR): ~4.5% (globally)
- Market Penetration by 2030: 10-15% of total AED market
- Expansion Opportunities: Adjunct uses in status epilepticus; pediatric and neonatal indications
- Regulatory Trends: Streamlined approval pathways for new indications, especially in emerging markets
| Year |
Estimated Market Size (USD billions) |
Notes |
| 2023 |
1.15 |
Post-pandemic recovery, growing epilepsy cases |
| 2025 |
1.35 |
Increased adoption, new clinical data |
| 2027 |
1.60 |
Expansion into new indications |
| 2030 |
USD 2.0 billion |
Potential for second-line therapy dominance in select regions |
Growth Drivers
- Increasing Prevalence: Over 50 million epilepsy patients globally.
- Long-acting Formulation Preference: Improved adherence, particularly among elderly and pediatric populations.
- Technological Innovations: Development of combination formulations, personalized dosing.
Market Risks
| Risk Factor |
Impact |
Mitigation Strategies |
| Patent Expirations |
Loss of exclusivity, price erosion |
Focus on lifecycle management |
| Competition |
Market share dilution |
Innovate within formulations and indications |
| Regulatory Delays |
Market entry postponement |
Early engagement with regulatory agencies |
| Reimbursement Limitations |
Reduced access |
Demonstrate cost-effectiveness |
Comparison with Competitors
| Aspect |
DILANTIN-30 |
GenBest AEDs (e.g., Lacosamide) |
Networked Therapies (e.g., AED combinations) |
| Formulation |
Extended-release |
Immediate and controlled |
Fixed-dose combinations |
| Dosing |
Once daily |
Once or twice daily |
Multiple doses, less adherence-focused |
| Indications |
General epilepsy |
Resistant epilepsy, status epilepticus |
Often adjuncts or multimodal therapies |
| Safety Profile |
Long-term safety well-established |
Slightly improved tolerability |
Variable, often higher adverse events |
Deep Dive: Regulatory Policies and Future Opportunities
- FDA and EMA pathways: Faster approval options for new indications using orphan drug status or breakthrough therapy designation.
- Off-label Potential: Use in neonatal epilepsy pending further trials.
- Digital Health Integration: Incorporation with adherence monitoring apps and remote patient management.
- Personalized Medicine: Pharmacogenomics to tailor dosing and minimize adverse effects.
Key Takeaways
- Clinical Development: Ongoing trials aim to expand indications and improve safety profiles, potentially elevating DILANTIN-30’s therapeutic positioning.
- Market Dynamics: The AED market is mature, driven by increased epilepsy prevalence, with DILANTIN-30 holding a significant share due to its long-acting formulation.
- Growth Opportunities: Pediatric, neonatal, and status epilepticus treatments offer promising expansion avenues.
- Competitive Edge: Proven safety and efficacy, combined with potential new indications, support continued market presence.
- Risks: Patent expirations and fierce competition require strategic lifecycle and innovation management.
FAQs
1. What are the primary advantages of DILANTIN-30 over immediate-release formulations?
Extended-release formulations improve patient adherence by reducing dosing frequency, often leading to more stable plasma drug levels, lower peak-related adverse effects, and enhanced long-term safety.
2. How does DILANTIN-30 compare to newer generation AEDs?
While newer AEDs may offer improved tolerability and fewer drug interactions, DILANTIN-30 remains cost-effective and well-established, with extensive clinical data supporting its safety profile.
3. Are there ongoing efforts to expand the indications for DILANTIN-30?
Yes; current clinical trials are exploring its use in juvenile epilepsy, neonatal seizures, and status epilepticus, which could broaden its market scope.
4. What are the main challenges facing DILANTIN-30 in the future?
Patent expirations leading to generic competition, emerging AED therapies with better tolerability, and regulatory hurdles for new indications are key challenges.
5. How might regulatory policies impact DILANTIN-30’s market share?
Streamlined approval pathways and orphan drug designations could facilitate expansion, whereas restrictions on off-label use or substitution policies might limit growth.
References
[1] ClinicalTrials.gov. “Ongoing and Completed Trials for DILANTIN-30,” 2023.
[2] IQVIA. “Global Antiepileptic Drugs Market Report,” 2022.
[3] U.S. Food and Drug Administration (FDA). “Labeling and Safety Updates for Phenytoin Sodium,” 2022.
[4] European Medicines Agency (EMA). “Review of Phenytoin and Extended-Release Formulations,” 2021.
[5] Market Research Future. “Antiepileptic Drugs Market Size and Forecast,” 2023.
